Multimodal AI for Early Pancreatic Cancer Detection
Official title: Multimodal AI Fusion Model for Early Detection for Pancreatic Cancer
Funded at Mayo Clinic Arizona · NIH-11401470 · Data updated 2026-11-12
A Mayo Clinic team is building an AI tool that combines CT scans and medical data to identify pancreatic cancer earlier in adults who don’t have symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | September 16, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,644,416 |
| NIH project number | 4R01CA289249-03 |
| Project ID | NIH-11401470 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults without symptoms who are at risk for pancreatic cancer and could benefit from early screening.
✕Less likely to help
Individuals without risk factors or those not undergoing CT imaging may not benefit.
What this research studies
This project aims to create PRECISE, a fusion AI model that uses both imaging features from abdominal CT scans and patient clinical data to predict pancreatic cancer risk before symptoms appear. Researchers will develop deep learning methods to automatically extract imaging biomarkers from CTs and apply debiasing to make the model fair across diverse groups and imaging settings. The model will be trained and validated with data from Mayo Clinic, Cornell, and UCSF to ensure broad applicability. If successful, the approach could enable clinicians to recognize high-risk individuals earlier and pursue timely follow-up.
Why it matters
Potential benefit: If successful, this could lead to earlier detection of pancreatic cancer and potentially improved outcomes through earlier treatment.
How similar studies have gone: Early imaging-based predictors for PDAC are being explored, but combinatorial multimodal fusion with debiasing is novel in this context.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Banerjee, Imon — Mayo Clinic Arizona
- Study coordinator: Banerjee, Imon
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.